Ixabepilone: a new active chemotherapy in the treatment of breast cancer.

Archive ouverte

Villanueva, Cristian | Vuillemin, Antoine Thiery | Demarchi, Martin | Bazan, Fernando | Chaigneau, Loïc | Pivot, Xavier, B.

Edité par CCSD -

International audience. Ixabepilone (BMS247550) is a semisynthetic derivative of the natural product that optimizes the properties observed with epothilone B. This compound has some similarities with taxanes in targeting and stabilizing microtubules, but it also has major differences. Interestingly, ixabepilone was evaluated in patients with well-characterized resistance to taxanes and was able to overcome the overexpression of multidrug resistance and was unaffected by mutations in the beta-tubulin genes. The interest in ixabepilone was clinically confirmed in Phase II and III clinical studies, which have demonstrated a strong activity in patients with metastatic breast cancer resistant to taxanes and in patients suffering from other types of chemoresistant tumors.

Consulter en ligne

Suggestions

Du même auteur

Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injury.

Archive ouverte | Curtit, Elsa | CCSD

International audience. Anthracycline extravasation is an uncommon but very serious complication. Very few data are available in the literature concerning the consequences and the management of extravasation of lipo...

Safety profile of new anticancer drugs.

Archive ouverte | Mansi, Laura | CCSD

International audience. Importance of the field: The development of targeted anticancer therapies stems from advances in molecular biology. New agents range from antibodies that form complexes with antigens on the s...

Is extracapsular tumour spread a prognostic factor in patients with early breast cancer?

Archive ouverte | Dobi, Erion | CCSD

International audience. BACKGROUND: This study searched for extra capsular tumour spread (ECS) as a prognostic factor for recurrence in terms of Disease Free Survival (DFS) and Overall Survival (OS). PATIENTS AND ME...

Chargement des enrichissements...